Accordingly, the treatment with QNZ, the NF-κB inhibitor, on TAMs significantly downregulates the expression of HSPG2, indicating that NF-κB pathway is involved in the remodeling of the tECM and in the tumor escaping from the immune system [116]. The gene discussed is NFKB1; the disease is neoplasm.